Operating expenses during the fourth quarter of 2024 were $25.8 million, an increase of $5.6 million, or 28%, compared to $20.2 million in the fourth quarter of 2023, mainly attributable to ...
10m
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at and via MiNK Therapeutics is a clinical-stage biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback